These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20635515)

  • 1. Novel delivery device for monolithical solid oral dosage forms for personalized medicine.
    Wening K; Breitkreutz J
    Int J Pharm; 2010 Aug; 395(1-2):174-81. PubMed ID: 20635515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral drug delivery in personalized medicine: unmet needs and novel approaches.
    Wening K; Breitkreutz J
    Int J Pharm; 2011 Feb; 404(1-2):1-9. PubMed ID: 21070842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
    Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
    AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of sustained and dual drug release co-extrusion formulations for individual dosing.
    Laukamp EJ; Vynckier AK; Voorspoels J; Thommes M; Breitkreutz J
    Eur J Pharm Biopharm; 2015 Jan; 89():357-64. PubMed ID: 25555454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of variation in extrusion speeds and temperatures on a PEO/PCL blend based matrix for oral drug delivery.
    Lyons JG; Blackie P; Higginbotham CL
    Int J Pharm; 2008 Mar; 351(1-2):201-8. PubMed ID: 18036753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.
    Thimmasetty J; Pandey G; Babu P
    Pak J Pharm Sci; 2008 Jul; 21(3):241-8. PubMed ID: 18614419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose.
    Yi T; Wan J; Xu H; Yang X
    Eur J Pharm Sci; 2008 Aug; 34(4-5):274-80. PubMed ID: 18541418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironmental pH modulation in solid dosage forms.
    Badawy SI; Hussain MA
    J Pharm Sci; 2007 May; 96(5):948-59. PubMed ID: 17455349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate.
    Chakraborty S; Shukla D; Vuddanda PR; Mishra B; Singh S
    J Pharm Pharmacol; 2011 Jun; 63(6):774-9. PubMed ID: 21585374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13.
    Potluri RH; Bandari S; Jukanti R; Veerareddy PR
    Arch Pharm Res; 2011 Jan; 34(1):51-7. PubMed ID: 21468915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot-melt extruded drug-loaded rods: evaluation of the mechanical properties for individual dosing via the Solid Dosage Pen.
    Laukamp EJ; Thommes M; Breitkreutz J
    Int J Pharm; 2014 Nov; 475(1-2):344-50. PubMed ID: 25195728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of agglomerated carvedilol by hot-melt processes in a fluid bed and high shear granulator.
    Kukec S; Dreu R; Vrbanec T; Srčič S; Vrečer F
    Int J Pharm; 2012 Jul; 430(1-2):74-85. PubMed ID: 22486965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of poloxamer-based nanofibers for enhanced dissolution of carvedilol.
    Kajdič S; Vrečer F; Kocbek P
    Eur J Pharm Sci; 2018 May; 117():331-340. PubMed ID: 29514051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation.
    Pokharkar V; Khanna A; Venkatpurwar V; Dhar S; Mandpe L
    Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A biorelevant in vitro release/permeation system for oral transmucosal dosage forms.
    Delvadia PR; Barr WH; Karnes HT
    Int J Pharm; 2012 Jul; 430(1-2):104-13. PubMed ID: 22486954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH sensitive alginate-chitosan hydrogel beads for carvedilol delivery.
    Meng X; Li P; Wei Q; Zhang HX
    Pharm Dev Technol; 2011 Feb; 16(1):22-8. PubMed ID: 20028209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
    Sica DA
    Am J Cardiol; 2006 Oct; 98(7A):1L-4L. PubMed ID: 17023226
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel solubility-modulated granules through porosity osmotic pump for controlled carvedilol delivery.
    Song QL; Li P; Li YM
    Pharm Dev Technol; 2012; 17(6):666-76. PubMed ID: 21486184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly dimethyl diallyl ammonium coated CMK-5 for sustained oral drug release.
    Zhang C; Zhao Q; Wan L; Wang T; Sun J; Gao Y; Jiang T; Wang S
    Int J Pharm; 2014 Jan; 461(1-2):171-80. PubMed ID: 24300214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.